



NOXXON appoints Aram Mangasarian as CEO

Berlin, Germany and Boston, USA - July 14, 2015 - NOXXON Pharma has appointed Dr. Aram Mangasarian as the new CEO. He is taking over from Iain Buchanan, who will be nominated to join the Supervisory Board as a non-executive director.

Aram Mangasarian joined NOXXON in May 2010 where he has led business development as Chief Business Officer, working closely with Iain Buchanan on the Executive Committee of the Company.

Iain Buchanan, who took up his role as CEO of the company in September 2010, steps down from the operational day-to-day business, but will continue to work with the management team before he will rejoin the Supervisory Board as non-executive director.

Aram Mangasarian said: "Becoming the CEO of NOXXON is a new challenge which I am delighted to accept. The Company has developed a new class of therapeutics – Spiegelmers – whose intrinsic properties could help many patients respond more effectively to anti-cancer therapy. My intention is to focus our efforts around cancer where I believe our products could have the greatest impact."

- Ends -

Notes for Editors:

About NOXXON Pharma

NOXXON Pharma is a clinical-stage biopharmaceutical company developing Spiegelmers, a novel class of proprietary nucleic acid-based therapeutic agents built on a backbone of mirror-image nucleotides. Spiegelmers are chemically synthesized L-stereoisomer oligonucleotide aptamers, an immunologically passive alternative to antibodies. NOXXON has a diversified portfolio of clinical-stage Spiegelmer[®] therapeutics:

- NOX-A12 (olaptased pegol) binds and inhibits the human Chemokine CXCL12. Two Phase 2a studies of NOX-A12 suggest improved efficacy in combination with chemotherapy in Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL).
- NOX-H94 (lexaptetid pegol) binds and neutralizes the human peptide hormone hepcidin, a regulator of the iron metabolism. A Phase 2a trial showed positive effects of NOX-H94 in a ESA-hyporesponsive population.
- NOX-E36 (emapticap pegol) binds and inhibits the human Chemokine CCL2 that plays a role in diabetic nephropathy. NOX-E36 has completed a Phase 2a

exploratory study with Type 2 diabetes patients with proteinuria on top of standard of care with results that suggest that NOX-E36 may be the first therapeutic agent with disease-modifying potential in this indication.

The Spiegelmer[®] platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional candidates in discovery stage research.

About Dr. Aram Mangasarian

Aram Mangasarian has over 15 years experience in biotechnology and pharmaceutical business development. During the last 5 years he worked as CBO for NOXXON. He began his career at ExonHit Therapeutics (now Diaxonhit, Euronext: ALEHT) in May 2000, eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the strategic alliance with Allergan (NYSE:AGN). In October 2005 Aram Mangasarian joined Novoxel as Vice-President Business Development. In this capacity he concluded the licensing agreement for North American rights to the NXL104 beta-lactamase inhibitor with Forest Laboratories (NYSE:FRX) in January 2008, which provided for a €75m upfront payment, €75m in pre-commercial mile-stones and double-digit royalties. Aram Mangasarian was also a member of the team that negotiated the acquisition of Novoxel by AstraZeneca (NYSE:AZN) in March 2010 for up to \$505m.

Contact:

| NOXXON Pharma AG | Instinctif Partners |
|---|--|
| Emmanuelle Delabre T: +49-30-726247-0 edelabre@noxxon.com www.noxxon.com | Robert Mayer / Andreas Zunhammer T: +49-89-30905189-13 / -11 noxxon@instinctif.com |